Onglyza Class Action Lawsuit
Nadrich & Cohen Accident Injury Lawyers is actively retaining those who have suffered heart failure or death after taking Onglyza, as well as their loved ones.
Onglyza was linked with an increased risk of heart failure by a study its maker, AstraZeneca, only conducted after releasing the apparently dangerous medication onto the marketplace.
Call us at (800) 718-4658 for a free consultation if you or a loved one suffered from heart failure or died after taking Onglyza (saxagliptin). You may be eligible for a financial recovery which can help compensate for medical bills, pain and suffering, lost wages, loss of companionship and more. We will not charge a fee for our representation unless and until we obtain financial compensation for you.
How To Join The Onglyza Lawsuit
You may be eligible for financial compensation in an Onglyza lawsuit because it appears that AstraZeneca, the makers of Onglyza, should have known that the drug was linked with an increased risk of heart failure but failed to warn about this risk before putting the drug on the marketplace.
Onglyza is a type 2 diabetes medication. Type 2 diabetes is associated with an increased risk of cardiovascular disease. It is therefore critical that those who develop medications to treat type 2 diabetes adequately test their products to make sure they don’t increase the risk of cardiovascular adverse events in users before putting these drugs on the marketplace.
The FDA, in 2008, issued guidance stating that those applying for approval of new anti-diabetic drugs should demonstrate their medications aren’t associated with a dangerous increase in cardiovascular risk. Despite this, AstraZeneca only conducted a study on Onglyza’s cardiovascular effects after putting the drug on the market.
The study, entitled “Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus — Thrombolysis in Myocardial Infarction 53,” wasn’t published until 2013 and found that saxagliptin use was associated with a statistically significant increase in heart failure-related hospitalization.
The FDA then proceeded to review the raw study data and, in 2016, added a heart failure warning to the drug’s label.
We believe that AstraZeneca failed to perform adequate safety testing for Onglyza prior to putting the medication on the market.
California Onglyza Lawyers
Nadrich & Cohen Accident Injury Lawyers have vast experience handling dangerous drug cases, having represented victims of dangerous drugs such as Fen-Phen, Zantac and Elmiron since 1990. We know how to get the job done and prove pharmaceutical companies’ liability for injuries caused by their defective drugs.
We are contingency fee attorneys, meaning our only fee is a percentage of your recovery. No fee is charged if no recovery is made.
Call us at (800) 718-4658 if you or a loved one suffered from heart failure or death after taking Onglyza. You can also fill out the contact form on this page or use our live chat.